Intrasense SA

Intrasense SA, founded in 2004 and headquartered in Montpellier, France, is a medical technology company specializing in software solutions for medical imaging. Initially established by three engineers, the firm went public via an IPO on the Euronext Growth market in February 2012. A significant milestone occurred in June 2023, when the Guerbet Group, a global specialist in contrast agents, became the majority shareholder, acquiring a 56.46% stake and making Intrasense a subsidiary. This strategic partnership aims to accelerate growth and innovation, particularly in integrating artificial intelligence into clinical workflows for oncology imaging.

The company's business revolves around the development and sale of software platforms that assist healthcare professionals in diagnosis, decision-making, and therapeutic monitoring. Its client base consists of over 1,200 hospitals and clinics across 40 countries, including a subsidiary in China and a distribution network spanning four continents. Revenue is generated through the licensing of its software platforms and related services such as installation, maintenance, and training.

Intrasense's flagship product is Myrian®, an advanced visualization software platform. Launched in 2004, Myrian® is a Class II medical device that enables the review, analysis, and processing of multimodal medical images like MRI and CT scans. It features a comprehensive suite of clinical applications, including specialized modules for cardiovascular, liver, prostate, and lung analysis (XP-Vessel, XP-Liver, XP-Prostate, XP-Lung). The platform is designed to be fully integrated into existing healthcare information systems, improving workflow efficiency for radiologists.

Since 2021, Intrasense has been developing Liflow®, a cloud-based platform specifically for oncology. Liflow® facilitates multidisciplinary collaboration and enhances the longitudinal follow-up of cancer patients. It uses artificial intelligence to automate lesion detection and measurement, integrating tools like the RECIST 1.1 score to track tumor progression. The platform also includes DUOnco™, a range of autonomous AI modules for detecting specific lesions in the liver, bones, and pancreas, developed in collaboration with Guerbet.

Nicolas Reymond served as CEO from 2018 to 2024, leading the company's restructuring and its sale to the Guerbet Group. His background includes a degree in electronics and signal processing and over a decade at Philips Healthcare in various roles. He was succeeded by Alexandre Salvador. The company continues to invest heavily in R&D, working closely with clinical partners to refine its AI-driven solutions for earlier and more accurate disease detection.

Keywords: medical imaging software, radiology, oncology, advanced visualization, AI in healthcare, diagnostic software, therapeutic follow-up, multimodality imaging, Myrian platform, Liflow platform, Guerbet subsidiary, MedTech, clinical decision support, RECIST 1.1, longitudinal patient monitoring, lesion detection, DICOM, PACS integration, digital health, cancer diagnosis